Nephrotoxicity with cyclooxygenase 2 inhibitor use in children

Pediatric Nephrology

Volumn 21, Issue 12, 2006, Pages 1893-1897

  Fletcher, Jeffery T ^a   Graf, Nicole ^c   Scarman, Anthony ^a   Saleh, Hamda ^c   Alexander, Stephen I ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Analgesic nephropathy; ARF; COX 2 inhibitors; Kidney; Pediatrics

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; LISINOPRIL; NAPROGESIC; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SCOPOLAMINE BUTYL BROMIDE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ARTHRALGIA; ARTICLE; BARTTER SYNDROME; CASE REPORT; CREATININE BLOOD LEVEL; DRUG USE; DYSMENORRHEA; FEMALE; FOLLOW UP; GASTRITIS; HUMAN; HYPERKALEMIA; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; METABOLIC ACIDOSIS; NEPHROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; RHEUMATIC FEVER;

ADOLESCENT; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; INFANT; KIDNEY; KIDNEY FAILURE, ACUTE; LACTONES; MALE; SULFONES;

EID: 33750996131     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0252-x     Document Type: Article

References (25)

1. Nanra RS (1993) Analgesic nephropathy in the 1990's - an Australian perspective. Kidney Int Suppl 42:S86-S92
2. Whelton A (1999) Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106(5B):13S-24S
3. Rosert JA, Fischer EA (2003) Acute interstitial nephritis. In: Johnson RJ, Feehally J (eds) Comprehensive clinical nephrology. Harcourt Publishers Limited, Toronto, pp 769-777
4. Moghal NE, Hegde S, Eastham KM (2004) Ibuprofen and acute renal failure in a toddler. Arch Dis Child 89:276-277
5. Wattad A, Feehan T, Shepard FM, Youngberg G (1994) A unique complication of nonsteroidal antiinflammatory drug use. Pediatrics 93:693
6. Barkin RL, Buvanendran A (2004) Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. Am J Therapeut 11:124-129
7. Chan FKL, Hung LCT, Suen BY, Wu JCY, Lee KC, Leung VKS, Hui AJ, To KF, Leung WK, Wong VWS, Chung S, Sung JY (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104-2110
8. Papaioannides D, Bouropoulos C, Sinapides D, Korantzopoulos P, Akritidis N (2001) Acute renal dysfunction associated with selective COX-2 inhibitor therapy. Int Urol Nephrol 33:609-611
9. Rocha JL, Fernandez-Alonso J (2001) Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 357:1946-1947
10. Esteve JB, Launay-Vacher V, Brocheriou I, Grimaldi A, Izzedine H (2005) Cox-2 inhibitors and acute interstitial nephritis: A case report and review of the literature. Clin Nephrol 63:385-389
11. Reinalter SC, Jeck N, Brochhausen C, Watzer B, Nusing RM, Seyberth HW, Kornhoff M (2002) Role of cyclooxygenase-2 in hyper prostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 62:253-260
12. Haas NA, Nossal R, Schneider CH, Lewin MA, Ocker V, Holder M, Uhlemann, F (2003) Successful management of an extreme example of neonatal hyper prostaglandin-E syndrome (Bartters' syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib. Pedaitr Crit Care Med 4:249-251
13. Vaisbich MH, Fujimura MD, Koch VH (2004) Bartter syndrome: Benefits and side effects of long-term treatment. Pediatr Nephrol 19:858-863
14. Zhao SZ, Reynolds MW, Lefkowith JB, Whelton A, Arellano FM (2001) A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organisation/Uppsala Monitoring Centre safety database. Clin Therapeut 23:1478-1491
15. Swan S, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht L, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Qua H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater DC, Yao SL (2000) Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized controlled trial. Ann Int Med 133:1-9
16. Norwood VF, Morham SG, Smithies OS (2000) Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int 58:2291-2300
17. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528
18. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs Nonsteroidal Anti-Inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: A randomized controlled trial. JAMA 284:1247-1255
19. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102
20. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:2581-2588
21. Nussmeir NA, Whelton A, Brown M, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005) Complications of the cox-2 inhibitors Parecoxib and Valdecoxib after cardiac surgery. N Engl J Med 352:1081-1091
22. Kerr SJ, Mant A, Horn FE, McGeechan K, Sayer GP (2003) Lessons from early large scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 179:403-407
23. Salazar JC (2003) Pediatric clinical trial experience: Government, child, parent and physician's perspective. Pediatr Infect Dis J 22:1124-1127
24. Caldwell PH, Murphy SB, Butow PN, Craig JC (2004) Clinical trials in children. Lancet 364:803-811
25. Young D (2005) FDA labors over NSAID decisions: Panel suggests COX-2 inhibitors stay available. Am J Health Syst Pharm 62:668-672